221 related articles for article (PubMed ID: 32209638)
1. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Drakes DJ; Rafiq S; Purdon TJ; Lopez AV; Chandran SS; Klebanoff CA; Brentjens RJ
Cancer Immunol Res; 2020 Jun; 8(6):743-755. PubMed ID: 32209638
[TBL] [Abstract][Full Text] [Related]
2. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
3. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
[TBL] [Abstract][Full Text] [Related]
4. Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
Tucker CG; Mitchell JS; Martinov T; Burbach BJ; Beura LK; Wilson JC; Dwyer AJ; Singh LM; Mescher MF; Fife BT
J Immunol; 2020 Sep; 205(5):1449-1460. PubMed ID: 32737148
[TBL] [Abstract][Full Text] [Related]
5. Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens.
Geng D; Zheng L; Srivastava R; Velasco-Gonzalez C; Riker A; Markovic SN; Davila E
Cancer Res; 2010 Oct; 70(19):7442-54. PubMed ID: 20807806
[TBL] [Abstract][Full Text] [Related]
6. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
Bowers JS; Nelson MH; Kundimi S; Bailey SR; Huff LW; Schwartz KM; Cole DJ; Rubinstein MP; Paulos CM
Clin Cancer Res; 2015 Jun; 21(11):2546-57. PubMed ID: 25904754
[TBL] [Abstract][Full Text] [Related]
7. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
8. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
Lo AS; Ma Q; Liu DL; Junghans RP
Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
[TBL] [Abstract][Full Text] [Related]
9. SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint.
Hajaj E; Eisenberg G; Klein S; Frankenburg S; Merims S; Ben David I; Eisenhaure T; Henrickson SE; Villani AC; Hacohen N; Abudi N; Abramovich R; Cohen JE; Peretz T; Veillette A; Lotem M
Elife; 2020 Mar; 9():. PubMed ID: 32122464
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
[TBL] [Abstract][Full Text] [Related]
11. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.
Díaz-Montero CM; El Naggar S; Al Khami A; El Naggar R; Montero AJ; Cole DJ; Salem ML
Cancer Immunol Immunother; 2008 Apr; 57(4):563-72. PubMed ID: 17726606
[TBL] [Abstract][Full Text] [Related]
12. Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
Dillard P; Köksal H; Maggadottir SM; Winge-Main A; Pollmann S; Menard M; Myhre MR; Mælandsmo GM; Flørenes VA; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
Mol Ther; 2021 Mar; 29(3):1199-1213. PubMed ID: 33212301
[TBL] [Abstract][Full Text] [Related]
13. Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control.
Kesarwani P; Chakraborty P; Gudi R; Chatterjee S; Scurti G; Toth K; Simms P; Husain M; Armeson K; Husain S; Garrett-Mayer E; Vasu C; Nishimura MI; Mehrotra S
Oncotarget; 2016 Oct; 7(43):69371-69383. PubMed ID: 27750220
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA
Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800
[TBL] [Abstract][Full Text] [Related]
15. Multifaceted Role of BTLA in the Control of CD8
Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
[No Abstract] [Full Text] [Related]
16. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
18. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.
Pouw N; Treffers-Westerlaken E; Kraan J; Wittink F; ten Hagen T; Verweij J; Debets R
Cancer Immunol Immunother; 2010 Jun; 59(6):921-31. PubMed ID: 20101507
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
Church SE; Jensen SM; Antony PA; Restifo NP; Fox BA
Eur J Immunol; 2014 Jan; 44(1):69-79. PubMed ID: 24114780
[TBL] [Abstract][Full Text] [Related]
20. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]